Will UN Report On Access To Medicines Change Anything?
Industry opposes interference with intellectual property rights but is open to compulsory licensing and delinking R&D cost to drug prices in limited situations.
You may also be interested in...
The report by the independent panel shows that the companies that develop and produce medicines, and the non-governmental organizations working on health issues at local level, still disagree fundamentally on the best way to go about improving access to those medicines. While R&D firms are skeptical of the report’s recommendations, the feeling among NGOs seems to be that this report represents something of a landmark development in the access debate.
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
GlaxoSmithKline PLC intends to make a big splash in the Medicines Patent Pool as the first company to share its future cancer drug patents for development of generic drugs in least developed and low-income countries and certain middle-income countries1.